Products
Online Inquiry
BFH772
Cat. No.:
OB0225WX-2732
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and HPLC.
Size:
Add to basket
Product Overview
Description:
BFH772 is a novel, orally active VEGFR2 inhibitor that targets the VEGFR2 kinase domain with a high-potency IC50 of 3 nM.
Synonym:
BFH 772; BFH-772; 890128-81-1; 6-((6-(hydroxymethyl)pyrimidin-4-yl)oxy)-N-(3-(trifluoromethyl)phenyl)-1-naphthamide; 1-Naphthalenecarboxamide, 6-((6-(hydroxymethyl)-4-pyrimidinyl)oxy)-N-(3-(trifluoromethyl)phenyl)-; 6-[[6-(hydroxymethyl)-4-pyrimidinyl]oxy]-N-[3-(trifluoromethyl)phenyl]-1-naphthalenecarboxamide; 6-[6-(hydroxymethyl)pyrimidin-4-yl]oxy-N-[3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide; 6-{[6-(hydroxymethyl)pyrimidin-4-yl]oxy}-N-[3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide; BFH 772; MFCD30534392; 6-(6-Hydroxymethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide
CAS No.:
890128-81-1
Compound CID:
24756034
Formula:
C23H16F3N3O3
Formula Weight:
439.39
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
BFH772 is applied in oncology research as a potent inhibitor of the VEGFR signaling pathway to study the disruption of tumor-induced angiogenesis and the restriction of nutrient supply to malignant tissues.
Library Information
Target:
VEGFR
Receptor:
VEGFR
Pathways:
Angiogenesis
Plate Number:
L6700-10
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
87 mg/mL; 198 mM
Ethanol Max Solubility:
87 mg/mL
ALogP:
4.396
HBA_Count:
4
HBD_Count:
2
Rotatable Bond:
6
